Diuretics and β-blockers: Is there a risk for dyslipidemia?

American Heart Journal

Volumn 139, Issue 1 I, 2000, Pages 174-184

  Weir, Matthew R ^a,c   Moser, Marvin ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CHOLESTEROL; DIURETIC AGENT; ENALAPRIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; PINDOLOL; PROPRANOLOL; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; ESSENTIAL HYPERTENSION; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; OBESITY; PRIORITY JOURNAL; SMOKING;

EID: 0033970797     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(00)90325-9     Document Type: Article

References (57)

1. Kannel WB. Blood pressure as a cardiovascular risk factor. JAMA 1996;275:1571-6.
2. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46.
3. Kaplan NM. Guidelines for the treatment of hypertension: an American view. J Hypertens 1995;13 suppl 2:S113-7.
4. Alderman MH. A review of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: the fifth report, 1993. Am J Hypertens 1993;6:896-8.
5. Lenfant C. High blood pressure: some answers, new questions, continuing challenges. JAMA 1996;275:1604-6.
6. Oparil S. Arterial hypertension. In: Wyngaarden JB, Smith LH, Bennett JC, editors. Cecil textbook of medicine. 19th ed. Philadelphia: WB Saunders; 1992. p. 253-69.
7. Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: data from the health examination surveys, 1960 to 1991. Hypertension 1995;26:60-9.
8. Bolli P, Fernandez PG, Buhler FR. Beta-blockers in the treatment of hypertension. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis and Treatment. New York: Raven Press; 1990. p. 2181-208.
9. Hebert PR, Moser M, Mayer J, Glynn RJ, Hennekens CH. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993;153:578-81.
10. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991;265:3301-2.
11. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Group. JAMA 1996;276:1886-92.
12. Neaton JD, Grimm RH Jr, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, et al. Treatment of mild hypertension study: final results. JAMA 1993;270:713-24.
13. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-64.
14. McInnes GT, Yeo WW, Ramsey LE, Moser M. Cardiotoxicity and diuretics: much speculation - little substance. J Hypertens 1992;10:317-35.
15. Flack JM, Cushman WC. Evidence for the efficacy of low-dose diuretic monotherapy. Am J Med 1996;101 Suppl 3A:53s-60s.
16. Conway J, Lauwers P. Hemodynamic and hypotensive effects of long-term therapy with chlorothiazide. Circulation 1960;21:21-7.
17. Tarazi RC, Dustan HP, Frohlich ED. Longterm thiazide therapy in essential hypertension; evidence for persistent alteration in plasma volume and renin activity. Circulation 1970;42:709-17.
18. van Brummelen P, Man in 't Veld AJ, Schalekamp MA. Hemodynamic changes during long-term thiazide treatment of essential hypertension in responders and nonresponders. Clin Pharmacol Ther 1980;27:328-36.
19. Cruickshank JM. The clinical importance of cardioselectivity and lipophilicity in beta blockers. Am Heart J 1980;100:160-78.
20. Kaplan NM, Gifford RW Jr. Choice of initial therapy for hypertension. JAMA 1996;275:1577-80.
21. Yusef S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovascular Dis 1985;17:335-71.
22. Eaton CB, Feldman HA, Assaf AR, et al. Prevalence of hypertension, dyslipidemia, and dyslipidemic hypertension. J Fam Pract 1994 38:17-23.
23. Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J 1986;112:432-7.
24. Day JL, Metcalfe J, Simpson CN. Adrenergic mechanisms in control of plasma lipid concentrations. Br Med J 1982;284:1145-8.
25. Frishman WH, Clark A, Johnson B. The effects of cardiovascular drugs on plasma lipids and lipoproteins. In: Frishman WH, Sonnenblick EH, eds. Cardiovascular pharmacotherapy. New York: McGraw Hill; 1997. p. 1515-59.
26. Ames RP, Hill P. Increase in serum lipids during treatment of hypertension with chlorthalidone. Lancet 1976;1:721-3.
27. Chrysant SG, Neller GK, Dillard B, Frohlich ED. Effects of diuretics on lipid metabolism in patients with essential hypertension. Angiology 1976;27:707-11.
28. Lasser NL, Grandits G, Caggiula AW, Cutler JA, Grimm RH Jr, Kuller LH, et al. Effects of antihypertensive therapy on plasma lipids and lipoproteins in the Multiple Risk Factor Intervention Trial. Am J Med 1984;76:52-66.
29. van Brummelen P, Gevers Leuven JA, van Gent CM. Influence of hydrochlorothiazide on the plasma levels of triglycerides, total cholesterol and HDL cholesterol in patients with essential hypertension. Curr Med Res Opin 1979;6:24-9.
30. Helgeland A. Treatment of mild hypertension: a five year controlled drug trial - the Oslo Study. Am J Med 1980;69:725-32.
31. Wilhelmsen L, Berglund G, Elmfeldt D, Fitzsimons T, Holzgreve H, Hosie J, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987;5:561-72.
32. Greenberg G, Brennan PJ, Miall WE. Effects of diuretic and betablockers therapy in the Medical Research Council Trial. Am J Med 1984;76 Suppl 2A:45-51.
33. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985;1:1349-54.
34. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992;304:405-12.
35. Williams WR, Schneider KA, Borhani NO, Schnaper HW, Slotkoff LM, Ellefson RD. The relationship between diuretics and serum cholesterol in hypertension detection follow-up participants. Am J Prev Med 1986;2:248-55.
36. Moser M. Lipid abnormalities and diuretics. Am Fam Physician 1989;40:213-20.
37. Weidmann P, Ferrier C, Saxenhofer H, Uehlinger DE, Trost BN. Serum lipoproteins during treatment with antihypertensive drugs. Drugs 1988;35 suppl 6:118-34.
38. Sowers JR. Metabolic changes associated with isradipine and hydrochlorothiazide in MIDAS: effects on serum cations and uric acid. In: Goodfriend T, et al, editors. Pharmacological control of calcium and potassium homeostasis. Dordrecht, The Netherlands: Kluwer Academic Publishers and Fondazione Giovanni Lorenzini; 1995. p. 185-95.
39. McKenney JM, Goodman RP, Wright JT Jr, Rifai N, Aycock DG, King ME. The effect of low-dose hydrochlorothiazide on blood pressure, serum potassium, and lipotroteins. Pharmacotherapy 1986;6:179-84.
40. Bielmann P, Leduc G. Effects of metoprolol and propranolol on lipid metabolism. Int J Clin Pharmacol Biopharm 1979;17:378-82.
41. Rosei EA, Palu DC, Leonetti G, et al. Clinical results of the verapamil in hypertension and atherosclerosis study. J Hypertens 1997;15:1337-44.
42. Moser M. Why are physicians not prescribing diuretics more frequently in the management of hypertension? JAMA 1998;279:1813-6.
43. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program (HDFP): reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979;242:2562-71.
44. Ferrari P, Rosman J, Weidmann P. Antihypertensive agents, serum lipoproteins and glucose metabolism. Am J Cardiol 1991;67:26B-35B.
45. Boehringer K, Weidmann P, Mordasini R, Schiffl H, Bachmann C, Riesen W. Menopause-dependent plasma lipoprotein alterations in diuretic treated woman. Ann Intern Med 1982;97:206-9.
46. Kovanen PT, Brown MS, Goldstein JL. Increased binding of low density lipoprotein to liver membranes from rats treated with 17-alpha-ethinyl estradiol. J Biol Chem 1979;254:1367-73.
47. Neutel JM. Metabolic manifestations of low-dose diuretics. Am J Med 1996;101 Suppl 3A:71s-82s.
48. Fogari R, Zoppi A, Pasotti C, Poletti L, Tettamanti F, Maiwald C. Effects of different beta-blockers on lipid metabolism in chronic therapy of hypertension. Int J Clin Pharmacol Ther Toxicol 1988;26:597-604.
49. Frithz G, Weiner L. Effects of bisoprolol on blood pressure, serum lipids and HDL-cholesterol in essential hypertension. Eur J Clin Pharmacol 1987;32:77-80.
50. Fogari R, Zoppi A, Tettamanti F, et al. Beta-blocker effects on plasma lipids in antihypertensive therapy: importance of the duration of treatment and the lipid status before treatment. J Cardiovasc Pharmacol 1990;16 suppl 5:S76-80.
51. Weiner L, Frithz G. Dose-effect relationship and long-term effects of bisoprolol in mild to moderate hypertension. J Cardiovasc Pharmacol 1986;8 suppl 11:S106-12.
52. Lithell H, Weiner L, Vessby B, Nordström ML. Effects of small doses of bisoprolol on blood pressure and lipoprotein concentrations in hypertensive patients. Eur J Clin Pharmacol 1993;44:19-22.
53. Bühler FR, Berglund G, Anderson OK, et al. Double-blind comparison of the cardioselective b-blockers bisoprolol and atenolol in hypertension: the bisoprolol international multicenter study (BIMS). J Cardiovasc Pharmacol 1986;8(suppl 11):S122-S127.
54. Cruickshank JM, Pennert K, Sörman AE, Thorp JM, Zacharias FM, Zacharias FJ. Low mortality from all causes, including myocardial infarction, in well-controlled hypertensives treated with a beta-blocker plus other antihypertensives. J Hypertens 1987;5:489-98.
55. Prisant LM, Weir MR, Papademetriou V, Weber MA, Adegbile IA, Alemayehu D. Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment. Am Heart J 1995;130:359-66.
56. Neutel JM, Rolf CN, Valentine SN, et al. Low-dose combination therapy as first line treatment of mild-to-moderate hypertension: the efficacy and safety of bisoprolol/HCTZ versus amlodipine, enalapril and placebo. Cardiovasc Rev Rep 1996;17:1-9.
57. Grimm RH Jr, Grandits GA, Prineas RJ, McDonald RH, Lewis CE, Flack JM, et al. Long-term effects on plasma lipids of diet and drugs to treat hypertension. JAMA 1996;275:1549-56.